<div id="readability-page-1"><p>Bank Julius Baer &amp; Co. Ltd Zurich cut its position in shares of  ResMed Inc. (NYSE:RMD - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,847 shares of the medical equipment provider's stock after selling 5,422 shares during the quarter. Bank Julius Baer &amp; Co. Ltd Zurich's holdings in ResMed were worth $6,031,000 as of its most recent SEC filing.</p><ul><li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li></ul><p>A number of other institutional investors and hedge funds also recently modified their holdings of RMD. International Assets Investment Management LLC purchased a new position in shares of  ResMed in the fourth quarter worth about $25,000.  ORG Partners LLC increased its holdings in shares of  ResMed by 181.6% in the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 69 shares during the period.  Imprint Wealth LLC bought a new stake in shares of  ResMed during the 3rd quarter valued at about $26,000.  WFA of San Diego LLC purchased a new position in  ResMed in the 2nd quarter worth approximately $26,000.  Finally, Sunbelt Securities Inc. purchased a new stake in shares of  ResMed during the 3rd quarter valued at $31,000. 54.98% of the stock is owned by hedge funds and other institutional investors. </p><h2>ResMed Stock Up 0.1%</h2><p>NYSE:RMD opened at $202.55 on Friday. ResMed Inc. has a 1-year low of $198.61 and a 1-year high of $293.81. The firm's 50-day moving average price is $225.07 and its 200-day moving average price is $242.81. The company has a market capitalization of $29.51 billion, a PE ratio of 19.53, a P/E/G ratio of 1.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. </p><p>ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $1.42 billion. During the same period in the previous year, the firm posted $2.37 EPS. The business's revenue for the quarter was up 10.8% compared to the same quarter last year.  On average, equities analysts predict that  ResMed Inc. will post 11.13 EPS for the current fiscal year. </p><h2>ResMed Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed's dividend payout ratio  is presently 23.14%. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts recently commented on RMD shares. KeyCorp reduced their target price on ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, April 27th. Wells Fargo &amp; Company decreased their price target on shares of ResMed from $270.00 to $227.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, May 1st. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Piper Sandler raised their price objective on ResMed from $270.00 to $275.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, January 30th. Finally, Citigroup lowered their target price on ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. One analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p><p><b>Read Our Latest Research Report on RMD</b></p><h2>Insider Buying and Selling</h2><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $251.03, for a total value of $1,252,890.73. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $117,035,959.69. This represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 18,973 shares of company stock valued at $4,386,031. 0.65% of the stock is owned by company insiders. </p><h2>ResMed Profile</h2> (Free Report)<p>ResMed <span>NYSE: RMD<span></span></span> is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.  </p><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than ResMed</li><li>YETI Rallies After Earnings Beat and Raised Outlook</li><li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li><li>Cisco’s Vertical Rally May Still Be in the Early Innings</li><li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li></ul><p><strong>Want to see what other hedge funds are holding RMD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ResMed Right Now?</h2><p>Before you consider ResMed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bank Julius Baer & Co. Ltd Zurich reduced its stake in ResMed Inc. by 17.9% in Q4, now holding 24,847 shares valued at $6,031,000. Other institutional investors also adjusted their positions. ResMed's stock opened at $202.55, with a market cap of $29.51 billion. The company reported a quarterly EPS of $2.86, exceeding estimates, and declared a dividend of $0.60 per share. Analysts have mixed ratings on the stock, with a consensus rating of 'Moderate Buy' and an average target price of $286.18.</p>

Market Beat

Resmed

iShares US Medical Devices

SPDR S&P Health Equip

HCA Healthcare

KeyCorp

Wells Fargo

JPMorgan Chase

Piper Sandler Cos

Citigroup

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD